---
schema_version: "secwatch.filing_event.v1"
accession: "0001599298-23-000096"
form_type: "8-K"
ticker: "SMMT"
cik: "0001599298"
company_name: "Summit Therapeutics Inc."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T15:28:47.806005+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Summit Therapeutics Q3 net loss $21.3M; starts second Phase III for ivonescimab

## Summary
- Net loss Q3 $21.3M; nine-month 2023 net loss $578.4M includes $520.9M one-time IPR&D charge from ivonescimab licensing.
- Cash, equivalents, and short-term investments $198.9M at Sep 30, 2023 (down from $648.6M Dec 2022); $100M notes payable due Sep 2024; expects funds into H2 2024.
- Enrollment initiated in HARMONi-3 Phase III trial for ivonescimab in first-line metastatic squamous NSCLC; HARMONi enrollment completion expected H2 2024.
- Manmeet S. Soni appointed COO and invested $5M; multiple internal promotions and hiring of Dr. Jack West and Dr. Laura Chow in clinical development.

## SEC filing metadata
- accession: 0001599298-23-000096
- form_type: 8-K
- ticker: SMMT
- cik: 0001599298
- company_name: Summit Therapeutics Inc.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1599298/000159929823000096/0001599298-23-000096-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1599298/000159929823000096/smmt-20231107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001599298-23-000096
- JSON: https://secwatch.observer/filing/0001599298-23-000096.json
- Plain text: https://secwatch.observer/filing/0001599298-23-000096.txt

## Key facts
- Earnings Releases
  Summit Therapeutics Inc. reported financial results for the third quarter and nine months ended September 30, 2023.
  - Period: the third quarter and nine months ended September 30, 2023
  - Result: reported results
  source text: Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the third quarter and nine months ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1599298/000159929823000096/0001599298-23-000096-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.